Atea Pharmaceuticals is trading 5% down at $4.73 on October 14, 2026, as biotech and broader markets weaken amid renewed interest-rate concerns following hotter-than-expected headline CPI. - The supplied sector context shows XBI down 2.01%; the S&P 500 and Nasdaq are also lower. - No new company-specific announcement appears on Atea Pharmaceuticals’ investor-relations release page; its latest listed release is dated September 8, with the prior release on August 12.